Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: modelling study
MetadataShow full item record
Objectives To predict the incremental lifetime effects, costs, and cost effectiveness of using human papillomavirus testing to triage women with borderline or mildly dyskaryotic cervical smear results for immediate colposcopy. Design Modelling study. Setting Three centres participating in NHS pilot studies, United Kingdom. Population Women aged 25-64 with borderline or mildly dyskaryotic cervical smear results. Interventions Screening using conventional cytology, liquid based cytology, and four strategies with different age cut-off points and follow-up times that used combined liquid based cytology and human papillomavirus testing (adjunctive human papillornavirus testing). Results The model predicts that compared with using conventional cytology without testing for human papillornavirus, testing for the virus in conjunction with liquid based cytology for women (aged 35 or more) with borderline or mildly dyskaryotic cervical smear results would cost 735 pound (E5528; $6474) per life year saved. Extending adjunctive human papillomavirus testing in combination with liquid based cytology to include women aged between 25 and 34 costs an additional 4233 pound per life year saved. Human papillornavirus testing is likely to reduce lifetime repeat smears by 52-86% but increase lifetime colposcopies by 64-138%. Conclusions Testing for human papillomavirus to manage all women with borderline or mildly dyskaryotic cervical smear results is likely to be cost effective. The predicted increase in lifetime colposcopies, however, deserves careful, consideration.
Cancer Screening Evaluation Unit (DoH)
License start date
BRITISH MEDICAL JOURNAL, 2006, 332 pp. 79 - 83
B M J PUBLISHING GROUP